• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 24, 2023
Discovery & Translation

ROTACs for transmembrane protein degradation; plus AntlerA’s lung regeneration therapy and more

BioCentury’s roundup of translational news
Read More
BioCentury | Sep 23, 2022
Discovery & Translation

PROTAC logic continues to evolve

New publications highlight bispecific antibody degraders as a way to eliminate a cell surface target
Read More
BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

BioCentury’s roundup of translational news
Read More
BioCentury | Dec 20, 2016
Distillery Therapeutics

Cancer

Read More
BioCentury | Jun 25, 2015
Distillery Therapeutics

Therapeutics: Ring finger protein 43 (RNF43); zinc and ring finger 3 (ZNRF3)

Read More
BioCentury | May 31, 2012
Distillery Therapeutics

Indication: Cancer

Read More
Items per page:
1 - 6 of 6
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa